Nociception Level Index (NOL Index) for Obstetrical Pain Assessment Under Epidural Analgesia.
NCT ID: NCT05898737
Last Updated: 2023-09-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
55 participants
OBSERVATIONAL
2023-06-20
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Since more than fifty years, the development of hospital obstetric assistance for labour, allowed the implementation of the pain relief culture in the demanding parturients population.
The ideal labour analgesic technique should provide consistent pain relief at any stage of labour, have a long duration of action, while being safe both for the mother and the foetus. It should also anticipate undesirable side effects, such as motor block.
The current gold standard for obstetric analgesia is the lumbar epidural technique using the administration of local anesthetics combined with opioids. However, the best administration mode is currently under debate, the main interest being the local anesthetic sparing responsible for various maternal side effects and the quality of maternal analgesia.
Despite the intense research in the field, the evaluation of the labour pain remains difficult as performed by the midwife and the anesthesiologist based on the patient's behaviour and her subjective self-assessment.
The PMD100™ (Medasense Biometrics Ltd., Ramat Yishai, Israel) is a non-invasive multiparametric nociception monitoring that has proved its interest in the intraoperative evaluation of patient's physiological response to pain under general anesthesia, using the NOL index variation. Nonetheless, it has been barely investigated in patients receiving locoregional anesthesia and never in the context of obstetrical pain.
The investigators support the idea that the NOL index monitoring could allow us to assess the degree of nociceptive stimulation related to obstetric labour and its variation under epidural analgesia, as well as to compare the efficacy of sensitive block using different epidural administration modes.
The aim of this pilot study is to evaluate the NOL Index variation during labour pain management with epidural analgesia.
The investigators will focus on the evaluation of analgesia in relation with the self-reported pain intensity, and secondly, the characteristics of the sensory block, the hemodynamic variables and side effects.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Incidence of Pruritus Using Intrathecal Fentanyl Versus Epidural Fentanyl to Initiate Labour Analgesia.
NCT07187427
Obstetrical Analgesia in the Estaing Hospital Maternity. A Prospective Database to Study the Determinants of Labor Pain and the Resulting Maternal Non Satisfaction.
NCT03314571
Remifentanil vs. Combined Spinal-epidural Analgesia for Labor Analgesia and Progress of Labor in Multiparous
NCT02963337
Compared Efficacy of Patient-controlled Epidural Analgesia With or Without Automatic Boluses
NCT03407209
Do Epidurals Placed at a Lower Level Improve Labor Analgesia?
NCT00954317
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators will conduct a prospective, repeated measures, monocentric, observational pilot study.
The study will be carried out in the anesthesia department of the Saint Pierre University Hospital in collaboration with the obstetrics department.
Parturient women in labour admitted into the delivery room, during the beginning of the first stage of labour demanding for an epidural will be recruited after signed written informed consent.
The number of patients to be included has been calculated to be 55.
2. Anesthetic management:
An epidural will be placed, initiated and maintained by the investigators according to the department's usual practice (including monitoring, technique and pump protocol).
The epidural will be considered successful when the sensitive block has reached a T10 level within maximum 30 minutes.
If the patient is not relieved within 30 minutes a new bolus readministration will be administered by the Patient-Controlled Epidural Analgesia (PCEA) pump.
In case of:
* Dura mater breach : exclusion of the patient from the protocol
* Venous puncture : epidural replacement at another level
* Hypotension (defined as a 20% drop in baseline blood pressure) needing vasopressors
* Hypotension and fetal heart rate abnormalities
3. Nociception monitoring NOL Index is based on several variables nonlinear combination of heart rate, heart rate variability, photoplethysmograph wave amplitude, skin conductance, skin conductance fluctuations, and their time derivatives and variation upon activation of the sympathetic nervous system in response to a stimuli. The normal range of the NOL index has been set between 10 and 25, a value above 25 indicates that the patient is experiencing a nociceptive stimulation.
The monitoring will be placed on the contralateral side to the non invasive blood pressure (NIBP) upon recruitment and it will be calibrated during 30 seconds to 2 minutes period of time without uterine contraction, objectified by the toco monitoring and confirmed by the parturient before epidural placement.
Consented patients will be taught how to use the 0-10 numeric rating scales (NRS) to report pain intensity (where zero indicates no pain and 10 indicates the worst possible pain).
The NOL monitor will be hidden throughout the procedure, to reduce any bias during self-reporting.
The patient will be asked to report the self-evaluated pain at each contraction using the NRS scale during the initial 15 minutes following the initial bolus.
The characteristics of the block achieved (sensory and motor), analgesic and hemodynamic variables will be collected throughout the study period (1 hour after the implementation of the epidural) at several time points as follows :
T0 - Epidural request T1 - End of loading dose (bolus) T2 - Loading dose + 15 mins T3 - Loading dose + 30 mins T4 - Loading dose + 45 mins T5 - Loading dose + 60 mins
If a supplementary bolus is needed (PCEA) all the aforementioned variables will be collected.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Parturients
Parturients on labour requiring an epidural
NOL-Index
NOL Index monitoring with the PMD100™ (Medasense Biometrics Ltd.)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NOL-Index
NOL Index monitoring with the PMD100™ (Medasense Biometrics Ltd.)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* American Society of Anesthesiologists (ASA) score I to II
* Gestational age \> 36 weeks of amenorrhea
* Primiparous or multiparous
* In labour
* Request and indication for epidural analgesia
* Height 160-175cm
* Intensity of pain objectified by Visual Analogue Scale (VAS) \> 3/10
Exclusion Criteria
* Contraindications to epidural analgesia (allergy to local anesthetics, coagulopathy, local infections)
* BMI \> 40 kg/m2
* Weight \> 110kg
* History of caesarean section
* Pre-eclampsia or pregnancy-induced hypertension
* Cardiac arrhythmias (including atrial fibrillation)
* Treatment with β-blockers
* Chronic opioid use
* History of substance abuse/dependency
* Psychiatric pathology (including depression, psychosis, etc.)
* Total language barrier
* Epidurals at uncomfortable times (night)
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire Saint Pierre
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Panayota Kapessidou, MD, PhD
Role: STUDY_DIRECTOR
Centre Hospitalier Universitaire Saint Pierre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Saint-Pierre
Brussels, Bruxelles-Capitale, Région de, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B0762023230305
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.